Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Jul 9, 2018 • 9:00 AM EDT
Ligand to Report Second Quarter 2018 Results on August 6th
Jun 27, 2018 • 9:00 AM EDT
Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement
May 18, 2018 • 8:00 AM EDT
Ligand Prices Offering of $650 Million of Convertible Senior Notes
Jun 19, 2018 • 8:30am PDT
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121
See all events
Jun 6, 2018 • 8:00am EDT
New York, NY
May 30, 2018
Aug 6, 2018 • 4:30pm EDT
$ALDX announces last patient dosed in dry eye disease Phase 2b clinical trial of topical ocular reproxalap https://t.co/QuViqPbvot
Roivant announced that OmniAb-derived RVT-1401 (previously HL161) will form foundation of a new company, Immunovant https://t.co/hNezPqrrQG
Opthea’s Phase 2b clinical trial of OPT-302 in Wet AMD reaches mid-way point of patient recruitment https://t.co/KNBBJFsV3i